ESA Bioscience benefits from CLIA waiver for rapid lead test, and FDA celebrates a "good moment"
This article was originally published in Clinica
Executive Summary
At-risk children in the US can now be screened for exposure to lead at their school or at a local clinic with an easy-to-use test that gives results in three minutes. The FDA is expanding the availability of blood-lead testing by granting a so-called CLIA waiver to ESA Bioscience for its LeadCare II system. This increases the potential market for the test from the 35,000 hospitals, private labs and large physician practices currently deemed capable of performing moderate and high-complexity testing to more than 115,000 certified point-of-care settings.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.